Form D · Other Investment Fund

Baker Brothers Life Sciences LP

New York, NY · CIK 0001363364

Offering snapshot reported Jul 1, 2026 · SEC filing

Reported sold: Yet to sell
Investors reported: 0
Minimum accepted: $0
First sale: Yet to occur

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 1, 2026	Initial	Yet to sell	No comparison	0	SEC filing
Oct 14, 2025	Initial	Yet to sell	No comparison	0	SEC filing
Aug 12, 2024	Amendment	$3,309,319,415	No comparison	101	SEC filing
Jul 14, 2023	Initial	Yet to sell	No comparison	0	SEC filing
Jul 1, 2022	Initial	Yet to sell	No comparison	0	SEC filing
Jul 1, 2020	Initial	Yet to sell	No comparison	0	SEC filing
Jul 2, 2018	Initial	Yet to sell	No comparison	0	SEC filing
Jul 12, 2016	Initial	Yet to sell	No comparison	0	SEC filing
Feb 17, 2016	Initial	Yet to sell	No comparison	0	SEC filing
Aug 13, 2014	Initial	$37,000,000	No comparison	3	SEC filing
Nov 14, 2013	Initial	$529,950,000	No comparison	31	SEC filing
May 15, 2012	Initial	$554,610,942	No comparison	45	SEC filing
Dec 30, 2010	Initial	Yet to sell	No comparison	0	SEC filing
Sep 18, 2008	Paper	Not reported	No comparison	Not reported	SEC filing
May 30, 2006	Paper	Not reported	No comparison	Not reported	SEC filing
May 15, 2006	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-589353

Source: Form D, filed Jul 1, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

BAKER BROTHERS LIFE SCIENCES, L.P.

Investment adviser: BAKER BROS. ADVISORS LP

Gross asset value: $25.8B
Beneficial owners: 392
ADV minimum commitment: $20M

Reported in Form ADV on Mar 27, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator SS&C FINANCIAL SERVICES LLC NEW YORK, New York, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Fund administrator SS&C FUND SERVICES (CAYMAN) LTD GRAND CAYMAN, Cayman Islands Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor ERNST & YOUNG LLP NEW YORK, New York, United States

Auditor ERNST & YOUNG LTD GRAND CAYMAN, Cayman Islands

Custodian GOLDMAN SACHS & CO. LLC NEW YORK, New York, United States Related to adviser: No

Custodian JPMORGAN CHASE BANK N.A. COLUMBUS, Ohio, United States Related to adviser: No

Custodian J.P. MORGAN SECURITIES LLC NEW YORK, New York, United States Related to adviser: No

Custodian THE BANK OF NEW YORK MELLON NEW YORK, New York, United States Related to adviser: No

Custodian THE NORTHERN TRUST COMPANY CHICAGO, Illinois, United States Related to adviser: No

Marketer IBK SECURITIES CO., LTD SEOUL, Korea, South Related to adviser: No

Prime broker GOLDMAN SACHS & CO. LLC NEW YORK, New York, United States

Prime broker J.P. MORGAN SECURITIES LLC NEW YORK, New York, United States

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: Yes

ERNST & YOUNG LLP
PCAOB 42

ERNST & YOUNG LTD
PCAOB 1655

GOLDMAN SACHS & CO. LLC
SEC 8-129

JPMORGAN CHASE BANK N.A.
LEI 7H6GLXDRUGQFU57RNE97

J.P. MORGAN SECURITIES LLC
SEC 8-35008

THE BANK OF NEW YORK MELLON
LEI HPFHU0OQ28E4NONFVK49

THE NORTHERN TRUST COMPANY
LEI 6PTKHDJ8HDUF78PFWH30

GOLDMAN SACHS & CO. LLC
CRD 361 · SEC 8-129

J.P. MORGAN SECURITIES LLC
CRD 79 · SEC 8-35008

Filing source

Form ADV 2060926 · Mar 27, 2026 · Schedule D 7.B.(1), fund 805-9378432489

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Julian Baker	Executive
Felix Baker	Executive
General Partner Of The General Partner Baker Brothers Life Sciences Capital (Gp), Llc	Promoter
N/A Baker Brothers Life Sciences Capital (Gp), Llc	Executive
General Partner Baker Brothers Life Sciences Capital, L.P.	Promoter
N/A Baker Brothers Life Sciences Capital, L.P.	Executive
Baker Brothers Life Sciences Capital, L.P.	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

860 Washington Street Third Floor
New York, NY, 10014